The HCPLive Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.
November 22nd 2024
In this analysis, the investigators systematically assessed links between the macronutrient profiles of common allergenic foods and corresponding prevalence of food allergy.
November 20th 2024
November 14th 2024
Device Maker Comments on Auto Injector Needles for Toddlers
Epinephrine auto-injectors can save lives in cases of anaphylaxis, but their needles are too long for toddlers and infants who weigh less than 15 kg, a device manufacturer confirms. The injectors can strike bone in small children.
Looking at the Future of Allergy & Asthma Treatment and Care
As more is learned about the causes of conditions like allergies and asthma medical science can better treat patients that are affected. This can include new treatments, new delivery methods, and new ways to prevent the conditions entirely.
Working Today to Help Tomorrow's Allergy and Asthma Patients
Looking at conditions like allergy and asthma on the cellular level may not help patients dealing with the conditions today, but work done in the field today can pay dividends for future generations of potential sufferers.
Researchers Look at Dust Mites and Potential Links to Allergies and Asthma
The number of patients dealing with health issues related to asthma and allergies continues to grow and researchers are looking to answer the question of why this is happening. The answer may be at the cellular level and be influenced by a person's environment, including the common dust mite.
Feeding Babies Gluten May Increase Risks for Celiac Disease
The risk of developing celiac disease might be increased in at-risk infants if they are fed gluten, according to findings from a study conducted in Sweden published in Clinical Gastroenterology and Hepatology.
New Indications for Psoriasis Drug Cosentyx Receive FDA Nod
Biologic drug secukinumab (Cosentyx/Novartis), already FDA approved in January 2015 to treat chronic plaque psoriasis, has now been approved for two new indications: the treatment of active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).